PRECLINICAL MEDICATIONS SCREENING

临床前药物筛选

• 批准号: 10683912
• 负责人: RICHARD L. BELL, PH.D.
• 金额: $ 39.77万
• 依托单位: TRUSTEES OF INDIANA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-29 至 2023-09-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10683912
• 关键词: Alcohol consumption; Clinical; Contracts; Controlled Clinical Trials; Data; Data Analyses; Data Reporting; Development; Elements; Evaluation; Fostering; Goals; Human; Infrastructure; Laboratories; Laboratory Study; Lead; Maintenance; Modeling; National Institute on Alcohol Abuse and Alcoholism; Pharmaceutical Preparations; Pharmacotherapy; Pre-Clinical Model; Process; Rattus; Standardization; Testing; Therapeutic; Work; alcohol abuse therapy; alcohol use disorder; blind; design; efficacy testing; interest; novel; pre-clinical; programs; screening

Developing medications for treatment of alcohol use disorder is a high priority for the National Institute on Alcohol Abuse and Alcoholism (NIAAA). NIAAA has initiated a Preclinical Medication Efficacy Testing Program to foster discovery of medication targets and lead compounds to treat alcohol use disorder. This program included the establishment of a coordinated infrastructure and network of preclinical laboratory models that can be employed to effectively screen potential therapeutics. A goal of this initiative was to facilitate the testing of clinically available pharmacotherapies as well as novel proprietary compounds in standardized preclinical models that capture key elements of alcohol use disorder. Recognized as a critical step in the medications development process, information generated from this preclinical work is designed to both inform subsequent efforts to advance the evaluation of candidate compounds in human laboratory studies and controlled clinical trials. This contract is for the blind efficacy testing of reference compounds and compounds of interest in preclinical models.

开发用于治疗酒精疾病的药物是美国国家酒精滥用和酒精中毒研究所（NIAAA）的重点。 NIAAA启动了一项临床前药物疗效测试计划，以促进发现药物靶标和铅化合物以治疗酒精饮酒障碍。 该计划包括建立一个协调的基础设施和临床前实验室模型网络，可用于有效筛选潜在的治疗剂。该计划的一个目的是促进在临床上可用的药物治疗以及标准化临床前模型中的新型专有化合物测试，以捕获酒精使用障碍的关键要素。 被公认为是药物开发过程中的关键步骤，这项临床前工作产生的信息旨在为后来的努力提供促进人类实验室研究中候选化合物的评估和对照临床试验的评估。 该合同是用于对临床前模型中参考化合物和感兴趣的化合物的盲功效测试。